This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Room temperature shipping (15°C to 25°C) to maintain medicine stability during transit.
Medicine Approved By:
• Food and Drug Administration (FDA)
Modeyso (dordaviprone)
General Description:
Modeyso (dordaviprone) is an oral targeted therapy used to treat diffuse midline glioma with H3 K27M mutation in patients with progressive disease after prior treatment. It targets tumor-driving pathways to help slow cancer progression.
Getting Modeyso (dordaviprone) in India:
Modeyso is FDA approved in the USA but not commercially available in India. Eligible patients can access Modeyso in India through the Named Patient Program (NPP) with a valid prescription.
MitoGENE assists with documentation, import approvals, and delivery in compliance with Indian regulations.
Disease Indications:
• Diffuse Midline Glioma (H3 K27M mutation)
• Progressive brain cancer after prior therapy
Available Dosage Form & Package:
• 125 mg capsules
How to Access Modeyso (dordaviprone) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Modeyso (dordaviprone) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
